Search

A patent application discusses the concomitant therapy of alternating electric fields and an N-cadherin inhibitor for treating cancer. N-cadherin, a glycoprotein involved in cell adhesion, is found to be aberrantly expressed in various cancers, impacting tumor progression. The therapy aims to prevent metastasis, reduce AKT phosphorylation, and inhibit PI3K/p85 recruitment to N-cadherin complexes. The method involves applying alternating electric fields and administering N-cadherin inhibitors to target cancer cells, potentially offering a novel approach to cancer treatment. [Extracted from the article]

Researchers at Zhejiang University School of Medicine have conducted a study on idiopathic pulmonary fibrosis (IPF) and its connection to non-small cell lung cancer (NSCLC). The study focused on the role of Secreted phosphoprotein 1 (SPP1) in the progression of both diseases, highlighting its impact on fibrosis and tumorigenesis. The findings suggest that SPP1 could be a potential therapeutic target for managing the co-occurrence of IPF and NSCLC. The research was supported by the National Natural Science Foundation of China and published in Respiratory Research. [Extracted from the article]

A recent study conducted at Hokkaido University Hospital focused on identifying prognostic factors for Japanese patients with non-small cell lung cancer (NSCLC) and brain metastases (BM) at initial diagnosis. The study, known as HOT 1701, involved a retrospective multicenter analysis of 566 patients with NSCLC and BM, revealing that patients with driver mutations had longer survival rates. The research identified six independent prognostic factors, leading to the development of a new prognostic model that stratified patients into low-, intermediate-, and high-risk groups based on their prognosis at diagnosis. This study may aid in determining the prognosis of NSCLC patients with BM. [Extracted from the article]

A recent study conducted at Fujian Cancer Hospital focused on the use of plasma epidermal growth factor receptor mutation (EGFRm) circulating tumor DNA (ctDNA) dynamics in predicting outcomes for patients with EGFRm-advanced non-small cell lung cancer (NSCLC). The study involved 98 treatment-naive patients who were administered icotinib until disease progression, with plasma samples collected at baseline and four weeks after treatment. Results showed that patients whose ctDNA became undetectable after treatment had significantly longer progression-free survival (PFS) and overall survival (OS) compared to those with detectable ctDNA after treatment. The study highlights the potential predictive value of ctDNA dynamics in treatment efficacy for NSCLC patients. [Extracted from the article]

A systematic review conducted by researchers at the University of Toronto evaluated the effectiveness of hypofractionated radiation therapy compared to conventionally fractionated radiation therapy in stage III non-small cell lung cancer patients. The review included a total of 1542 participants from various phase II and phase III trials, with results showing no evidence that hypofractionated regimens improved survival over conventionally fractionated radiation. The study also highlighted the importance of monitoring toxicity levels and maintaining normal tissue radiotherapy constraints during treatment. For more information, the full article can be accessed for free at the Cancers journal website. [Extracted from the article]

A study conducted at Duke University Medical Center in Durham, North Carolina, focused on the role of ferroptosis-related genes in predicting survival of non-small cell lung cancer (NSCLC) patients. Researchers identified two genetic variants, PARK7 rs225120 C>T and DDR2 rs881127 T>C, associated with NSCLC survival, potentially affecting gene expression levels. The study suggests that these genetic variants may play a role in influencing the survival outcomes of NSCLC patients. [Extracted from the article]

A recent study led by researchers at the University of Cincinnati has discovered a potential new method to enhance the effectiveness of radiation therapy for lung cancer that has spread to the brain. Lung cancer is a leading cause of cancer-related deaths in the United States, with non-small cell lung cancer being the most common type. The study focused on a drug called AM-101, which was found to activate certain receptors in lung cancer cells, making them more sensitive to radiation treatment. The researchers found that adding AM-101 to radiation therapy could improve outcomes for patients and reduce side effects. The team is now planning to conduct Phase 1 clinical trials to further investigate this promising combination treatment. [Extracted from the article]

A study conducted at the Miami Cancer Institute focused on the use of immune checkpoint inhibitors in managing brain metastases from non-small cell lung cancer (NSCLC). The research highlighted the efficacy of immune checkpoint inhibitors in combination with traditional treatments such as radiotherapy and chemotherapy, emphasizing the need for a personalized multidisciplinary approach to treatment. The study also emphasized the importance of further research to refine combination therapies and understand the optimal timing and sequence of treatments for NSCLC patients with brain metastases. [Extracted from the article]

Recent research from the University of Texas MD Anderson Cancer Center highlights the molecular landscape of ERBB2 alterations in 3000 advanced non-small cell lung cancer (NSCLC) patients. The study found that ERBB2 represents an actionable oncogenic driver in NSCLC, with specific alterations identified in both Chinese and US patient cohorts. The research emphasizes the importance of understanding ERBB2 alterations for guiding treatment decisions in NSCLC patients. The study also noted similarities in clinical characteristics between EGFR and ERBB2 exon 20 NSCLC cases, including low tumor mutation burden and a predominant never-smoker population. [Extracted from the article]

Researchers from the Second Affiliated Hospital of Shandong First Medical University in China discussed a case of lung squamous cell carcinoma with a novel FGFR3-IER5L fusion mutation responding to anlotinib treatment. Lung squamous cell carcinoma is the second most common type of non-small cell lung cancer, but treatment options are limited due to lower incidence of driver gene mutations. The patient in the case study achieved a partial response to anlotinib, a tyrosine kinase inhibitor, with a progression-free survival of 3.8 months. The study was published in Frontiers in Oncology and can be accessed for free online. [Extracted from the article]

The document discusses a patent issued for anti-TIGIT antibodies by Merck Sharp & Dohme LLC, focusing on the potential of inhibitory immune modulatory receptors in tumor immunotherapy. The invention provides detailed information on the structural and functional features of the antibodies, emphasizing their potential in treating cancer and infectious diseases. The patent outlines methods for administering the antibodies to human subjects with cancer or infections, highlighting the importance of combining them with other therapeutic agents. The research aims to enhance tumor-specific immune responses and transform cancer therapy by targeting inhibitory immune modulatory receptors effectively. [Extracted from the article]

Researchers at Mashhad University of Medical Sciences in Iran have developed a new method for treating non-small cell lung cancer using a combination of gene therapy and chemotherapy. The study involved the synthesis of a copolymer to encapsulate doxorubicin and MCL-1 CRISPR.Cas9 plasmid, which were then targeted to cancer cells using aptamers. The results showed enhanced therapeutic effects in both in vitro and in vivo studies, suggesting a potential safe treatment for lung cancer. The research has been peer-reviewed and offers promising insights for future clinical translation. [Extracted from the article]

Researchers at the National University of Singapore have developed a personalized treatment approach for non-small cell lung cancer (NSCLC) by using custom-designed antisense oligonucleotides (ASOs) to target specific mutations in the epidermal growth factor receptor (EGFR) gene. This strategy aims to overcome drug-resistant mutations and reduce toxicities associated with standard tyrosine kinase inhibitors (TKIs). By delivering EGFR-targeting ASOs via extracellular vesicles (EVs), the researchers have demonstrated promising results in inhibiting tumor growth in NSCLC models with EGFR mutations. This study highlights the potential of ASOs as an effective therapeutic platform for NSCLC treatment. [Extracted from the article]

The article discusses new research on neuroendocrine transdifferentiation (NEtD) in human cancer, highlighting its role as a resistance mechanism to targeted therapies in various cancer types. The study emphasizes the importance of understanding the molecular mechanisms underlying NEtD for developing novel therapies. The research provides insights into genetic alterations, DNA methylation, histone modifications, and other proteomic changes associated with NEtD, as well as the current management of targeted therapies in clinical practice. The study was conducted by researchers at the Department of Clinical Immunology and funded by the National Natural Science Foundation of China. [Extracted from the article]

The article discusses a global Phase III clinical trial, ARTEMIDE-Lung03, comparing the efficacy and safety of rilvegostomig and pembrolizumab in combination with platinum-based chemotherapy as a first-line treatment for non-squamous metastatic NSCLC expressing PD-L1. The trial aims to assess overall survival, progression-free survival, response rates, and patient-reported outcomes over approximately 5 years. The study involves 878 participants and is set to be completed by March 25, 2030, with eligibility criteria focusing on specific histological and genetic characteristics of non-squamous NSCLC. [Extracted from the article]

The article discusses a pilot study focusing on blood-based biomarkers to predict responses to immune checkpoint inhibitors in patients with non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). The study aims to evaluate changes in tumor fraction (TFx) during treatment and explore the roles of inflammation, glucocorticoid secretion, and ketosis in response to therapy. The study is observational, with a recruitment status of "RECRUITING" and an enrollment goal of 100 participants by December 31, 2025. The primary outcome measure is the percentage of patients with a >5% change in TFx during the first two treatment cycles. [Extracted from the article]

The article discusses a clinical trial, NCT06634199, focusing on the antitumor immune response in patients with non-resectable NSCLC after concurrent chemo-radiotherapy and immunotherapy treatment. The study is observational, non-comparative, and based on secondary data collected from patient clinical charts. It aims to describe the immune response generated in real-world settings. The trial is not yet recruiting, with a planned enrollment of 50 patients and a completion date of November 4, 2027. [Extracted from the article]

The article discusses a clinical trial, NCT06629714, focusing on the impact of pretreatment emotional distress on survival and the predictive role of peripheral biomarkers in immunotherapy response among treatment-naive, inoperable Gastroesophageal Cancer (GC) and non-small-cell lung cancer (NSCLC) patients. The study aims to explore the relationship between emotional distress, biomarkers, and immunotherapy outcomes in cancer patients. Various inflammatory markers and metabolic indicators are being evaluated longitudinally to assess their predictive value in treatment response. The trial is ongoing in China and involves 180 participants, with a completion date set for November 1, 2025. [Extracted from the article]

A recent study conducted at Henan Province People's Hospital in China explored the role of FOXA1 in regulating HER2 transcription to enhance the tumorigenic capacity of lung cancer through the PI3K/AKT pathway. The research suggests that FOXA1 could potentially serve as a biomarker or therapeutic target in non-small cell lung cancer treatments, with the possibility of the drug Disitamab vedotin (RC48) being a transformative agent in lung cancer therapy. The study highlights the importance of understanding the molecular mechanisms underlying lung cancer progression and the potential for targeted therapies to improve patient outcomes. [Extracted from the article]

Researchers at Peking University Third Hospital conducted a study on the effects of Helicobacter pylori infection on cancer development and immunotherapy. The research suggests that H. pylori infection may reduce the efficacy of immunotherapy for colorectal cancer, non-small cell lung cancer, and melanoma, but its effects on gastric cancer remain controversial. The study emphasizes the importance of understanding the role of H. pylori in cancer development and the need for further research to determine whether H. pylori eradication is necessary during immunotherapy for certain types of tumors. [Extracted from the article]

A recent study conducted by researchers at Nanjing Medical University in China compared the efficacy and safety of neoadjuvant, adjuvant, and perioperative immunotherapies in early-stage non-small cell lung cancer (NSCLC). The study, which included 10 randomized controlled trials involving 5569 NSCLC patients, found that perioperative immunotherapy was more effective than adjuvant immunotherapy, with significant benefits in certain subgroups. Neoadjuvant and perioperative immunotherapies improved pathologic response and event-free survival, while adjuvant immunotherapy enhanced disease-free survival. The study suggests that further research is needed to explore the differences in efficacy between neoadjuvant and perioperative immunotherapies in the entire population of resectable NSCLC patients. [Extracted from the article]

Researchers at Xinqiao Hospital in Chongqing, China, have identified new findings on lung cancer using RNA sequencing. They analyzed patient datasets to classify biological pathways and molecular subtypes, revealing three distinct phenotypes with different prognoses and therapeutic responses. The study also explored drug repositioning possibilities and highlighted a potential lineage factor that could be targeted for treatment. This research provides valuable insights into personalized treatment approaches for lung cancer patients. [Extracted from the article]

A recent study conducted in Beijing, China, explored the effectiveness of neoadjuvant immunochemotherapy in patients with resectable non-small cell lung cancer (NSCLC). The study found that patients who received neoadjuvant immunochemotherapy had higher pathologic complete response rates compared to those who received chemotherapy alone. Additionally, adjuvant therapy was identified as a factor that could prolong disease-free survival in patients undergoing neoadjuvant immunochemotherapy. The study concluded that neoadjuvant immunochemotherapy showed superior efficacy over chemotherapy alone for NSCLC patients. [Extracted from the article]

A recent study conducted at the Medical University of Innsbruck in Austria explored the impact of soluble PD-L1 (sPD-L1) on T cells, relapse-free survival, and overall survival in early-stage non-small cell lung cancer (NSCLC). The research found that high levels of sPD-L1 were associated with reduced survival and treatment failure in advanced stages of NSCLC. However, the study's results were inconclusive, highlighting the need for further investigation and validation in larger trials to determine the clinical relevance of sPD-L1 in early-stage NSCLC. [Extracted from the article]

A study conducted at Duke Cancer Institute in Durham, North Carolina, examined the impact of early specialist palliative care (PC) involvement on patients with metastatic non-small cell lung cancer (mNSCLC). The research found that early PC consultation was associated with improved quality of life, less aggressive end-of-life care, and longer survival. Despite the benefits of early PC integration, referrals to PC in mNSCLC still occur late or not at all. This real-world study highlights the importance of timely PC involvement in improving end-of-life care outcomes for patients with mNSCLC. [Extracted from the article]

A report from Guangzhou Medical University in the People's Republic of China discusses the need for new drug targets in non-small cell lung cancer (NSCLC) to improve treatment outcomes. The study identified seven candidate druggable genes for NSCLC, including CD33, ENG, ICOSLG, and IL18R1 for lung adenocarcinoma, and VSIR, FSTL1, and TIMP2 for lung squamous cell carcinoma. The research suggests that drugs targeting genetically supported genomes may offer promising efficacy in clinical trials, providing genetic evidence to prioritize drug development for NSCLC. [Extracted from the article]

A recent study from the University of California Los Angeles (UCLA) highlights the importance of precision medicine in treating non-small cell lung cancer. The research emphasizes the need for analyzing tumor tissues for genomic alterations and protein expression to select effective therapies. The study discusses the incorporation of systemic therapies into neoadjuvant and adjuvant regimens to improve survival outcomes for patients with early-stage non-small cell lung cancer. For more information, readers can refer to the Journal of Thoracic and Cardiovascular Surgery. [Extracted from the article]

Researchers from The University of Texas MD Anderson Cancer Center found that patients with specific mutations in the STK11 and/or KEAP1 genes who have metastatic non-squamous non-small cell lung cancer may benefit from adding the immunotherapy tremelimumab to a combination of durvalumab and chemotherapy. The study, published in Nature, suggests that these mutations could serve as biomarkers to identify patients who would benefit from dual immune checkpoint inhibition. The addition of tremelimumab to durvalumab and chemotherapy resulted in higher overall response rates for these patients, supporting the use of dual checkpoint inhibitors for this subset of patients. The study was conducted through collaboration between academic centers in North America and Europe, as well as biotechnology and pharmaceutical companies. [Extracted from the article]

The article discusses the use of a phosphodiester-backboned bottlebrush polymer as a carrier for aptamers targeting the receptor tyrosine kinase AXL, which is associated with drug resistance in cancer treatment. The conjugate, termed pacDNA, improves aptamer specificity in vivo, prolongs blood retention, and enhances overall aptamer bioactivity. In experiments with AXL-overexpressing cell lines and a non-small cell lung cancer xenograft model, pacDNA treatment showed promising results in inhibiting AXL phosphorylation and reducing cancer cell migration and invasion, suggesting the potential of bottlebrush polymers in aptamer therapeutics. [Extracted from the article]

The article discusses a clinical trial, NCT06634056, focusing on preventing lung injury in stage III non-small cell lung cancer patients undergoing chemoradiation. The trial aims to evaluate the addition of Pentoxifylline and a-Tocopherol to standard care treatment to reduce side effects related to lung injury and improve quality of life. The study is a Phase II, double-blind, placebo-controlled randomized trial with a recruitment goal of 150 participants, and the primary completion date is set for November 30, 2030. The trial is being conducted by the University Health Network in Toronto, with collaborators including AstraZeneca. [Extracted from the article]

A patent application titled "Antibodies Targeting Liv-1 And Uses Thereof" was published online on October 3, 2024, by inventors from Shanghai, China. The application focuses on developing antibodies against the liver receptor homolog 1 (LIV-1) protein, which is involved in regulating cellular processes and is expressed in various tissues, including breast and prostate. The antibodies aim to improve therapeutic efficacy and safety for cancer treatments, particularly in estrogen receptor-positive breast cancers and prostate cancers. The application also discusses the potential use of antibody-drug conjugates for cancer treatment, targeting a range of cancer types such as bladder, liver, colon, breast, and prostate cancer. [Extracted from the article]

A patent has been issued for tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha by Arcus Biosciences Inc. The compounds aim to inhibit the activity of hypoxia-inducible factor (HIF) family of transcription factors, particularly HIF-2a, which is associated with poor clinical outcomes in various cancers. These inhibitors could potentially be used to treat diseases and disorders such as cancer, inflammation, autoimmune disorders, and metabolic disorders. [Extracted from the article]

Researchers at the Affiliated Hospital of Inner Mongolia Medical University conducted a study on the effects of toadflax (bufalin) on erlotinib resistance in nonsmall cell lung cancer (NSCLC) by inhibiting the fibroblast growth factor receptor (FGFR). The study found that bufalin inhibited FGFR by reversibly binding to FGFR1, leading to a reduction in the expression levels of FGFR, FRS2, ERK, and S6 proteins in lung cancer cells. Additionally, the combination of bufalin and erlotinib significantly inhibited the growth of erlotinib-resistant tumors and induced apoptosis in NSCLC cells. This research suggests that bufalin could potentially reverse erlotinib resistance in NSCLC by inhibiting FGFR expression. [Extracted from the article]

Researchers at Gansu University of Chinese Medicine conducted a study on the potential of Astragalus membranaceus-derived small molecule isoliquiritigenin (ISL) to enhance radiotherapy sensitivity in lung cancer cells. The study aimed to attenuate the carbon ion radiation-induced bystander effect in bone marrow mesenchymal stem cells (BMSCs) during lung cancer treatment. The findings suggest that ISL combined with carbon ion radiotherapy had a significant anti-tumor effect and protected BMSCs from radiation damage, indicating a promising treatment option for non-small cell lung cancer. The research provides a theoretical foundation for further clinical development of ISL as a potential radiosensitizer. [Extracted from the article]

A recent study conducted at Texas A&M University explored the role of exosomal miRNAs in modulating the oncogenic LINE-1 regulatory network in non-small cell lung cancer (NSCLC). The research found that specific miRNAs enriched in circulating exosomes of NSCLC patients could distinguish cancer cases from controls and influence gene expression within the LINE-1 regulatory network. Exosomes from late-stage NSCLC patients were shown to activate oncogenic signaling in recipient lung bronchial epithelial cells, raising questions about lung cancer progression and potential therapeutic interventions. For more information, the full article can be accessed in the International Journal of Molecular Sciences. [Extracted from the article]

Researchers at Mohammed V University in Rabat conducted a study on non-small cell lung cancer (NSCLC) in Moroccan patients using targeted next-generation sequencing. The study analyzed genetic alterations in 76 NSCLC samples, identifying targetable genetic alterations in genes like EGFR, KRAS, and MET. The research highlighted the importance of next-generation sequencing in identifying actionable mutations in NSCLC patients, emphasizing its value in clinical diagnostic settings. The study also compared the prevalence of mutated genes in Moroccan patients with the Cancer Genome Atlas database, revealing differences in gene mutations between the two populations. [Extracted from the article]

The article discusses new research findings on non-small cell lung cancer, highlighting the importance of early detection in reducing complications and improving treatment outcomes. Various methods such as EB-OCT and liquid biopsy have shown promise in detecting biomarkers with high sensitivity and specificity. While low-dose CT scan remains the standard screening procedure, researchers are exploring new approaches, including combining different methods, to decrease false-positive results and enhance early detection rates. [Extracted from the article]

A recent study conducted by researchers at Yonsei University College of Medicine in Seoul, South Korea, focused on the role of Ubiquitin C-terminal hydrolase L1 (UCHL1) in non-small cell lung cancer (NSCLC). The study found that UCHL1 overexpression is associated with aggressive tumor growth and poor survival outcomes in NSCLC patients. The research suggests that UCHL1 may serve as an effective biomarker for NSCLC. This study highlights the importance of understanding the molecular mechanisms underlying lung cancer progression for improved diagnosis and treatment strategies. [Extracted from the article]

A recent study conducted at Free University Berlin focused on the prognostic factors for patients with advanced non-small cell lung cancer (NSCLC) undergoing paclitaxel/platinum chemotherapy. The study integrated baseline blood biomarker concentrations and tumor growth kinetics to predict overall survival (OS) in patients receiving chemotherapy. The research highlighted the importance of combining paclitaxel exposure-driven tumor response and baseline blood C-reactive protein (CRP) concentrations for individual prognostic predictions in NSCLC patients. The findings aim to optimize treatment decisions and dosing regimens for paclitaxel/platinum-based chemotherapy in advanced NSCLC patients. [Extracted from the article]

Researchers at the University of Texas MD Anderson Cancer Center have conducted a study on non-small cell lung cancer, which remains a leading cause of cancer deaths globally. The study focused on the impact of intratumor heterogeneity on prognostication in localized non-small cell lung cancer, using multiregional RNA-seq data to analyze gene expression and immune cell infiltration levels. The findings suggest that considering RNA-ITH is crucial for optimizing expression-based prognostic biomarkers and models, with multiregional assays showing potential for improved prognostic stratification. The research was published in npj Precision Oncology and can be accessed for free online. [Extracted from the article]

A recent study conducted by Tianjin Medical University Cancer Institute and Hospital evaluated the efficacy and safety of camrelizumab-based comprehensive treatment for non-small cell lung cancer (NSCLC). The study included data from 5 randomized controlled trials, 2 cohort studies, and 12 single-arm studies, showing that camrelizumab-based combination treatment significantly extended overall survival (OS), progression-free survival (PFS), and event-free survival (EFS) in NSCLC patients. The research concluded that camrelizumab combined with chemotherapy is an effective treatment option for NSCLC patients, providing good safety and improved outcomes. [Extracted from the article]

A recent study conducted at the Netherlands Cancer Institute focused on the pharmacokinetics of the macrocyclic anaplastic lymphoma kinase (ALK) inhibitor Zotizalkib in mouse models. The research found that the brain exposure to Zotizalkib is restricted by the ABCB1 efflux transporter and its plasma disposition is influenced by mouse carboxylesterase 1c. These findings could potentially aid in the development and optimization of therapeutic efficacy and safety of Zotizalkib and similar ALK inhibitors. The study was financially supported by the Netherlands Cancer Institute and has been peer-reviewed. [Extracted from the article]

A recent study conducted at the Sri Sathya Sai Institute of Higher Learning in Andhra Pradesh, India, focused on the design, synthesis, and evaluation of novel 4-aminopyrazolo[3,4-d]pyrimidine derivatives as potential anti-cancer agents against renal cancer cells. The research identified several compounds with inhibitory activity against different cancer cell lines, with compounds 12c, 12d, 12f, 12j, and 11 showing promising results against renal cancer cells. These findings suggest the need for further pharmacological investigation of these compounds as potential anti-cancer candidates. [Extracted from the article]

Researchers from Guizhou Medical University have developed a deep learning model to predict the response of non-small cell lung carcinoma (NSCLC) patients to concurrent chemoradiotherapy (CCRT). The model, based on contrast-enhanced computed tomography (CT) images, showed promising predictive performance with an area under the curve of 0.86 in the training cohort and 0.84 in the validation cohort. The study also explored biological signaling pathways associated with the DL model and found it to be positively related to cell adhesion molecules, the P53 signaling pathway, and natural killer cell-mediated cytotoxicity. This research contributes to understanding treatment responses in NSCLC patients undergoing CCRT. [Extracted from the article]

Researchers at the Korea Brain Research Institute conducted a study on the effects of erlotinib, an EGFR inhibitor used in lung cancer treatment, on Alzheimer's disease (AD) pathology in mouse models. The study found that erlotinib improved short-term memory, reduced tau phosphorylation, and decreased astrogliosis in AD mouse models. These results suggest that erlotinib could be a potential therapeutic drug for alleviating AD symptoms. The study was published in Frontiers in Immunology and was supported by various research foundations. [Extracted from the article]

A new report from researchers at the Third Xiangya Hospital of Central South University discusses findings on non-small cell lung cancer. The study evaluated the use of clinical target volume (CTV) omission in stage III patients treated with 4D-CT Intensity-Modulated Radiation Therapy (IMRT). The researchers found that CTV omission was not suitable for stage III patients when the prescribed dose to the planning target volume (PTV) was 60 Gy. However, further exploration is warranted for CTV omission with a higher dose to the PTV. The study also found that the simultaneous integrated boost (SIB) IMRT plan provided the best protection to normal tissue. [Extracted from the article]

A recent study conducted by researchers from the University of Camerino in Italy explored the potential of gold compounds as inhibitors of non-small cell lung cancer (NSCLC) cell growth. The study found that certain gold compounds with specific ligand arrangements exhibited the highest cytotoxicity against lung cancer cells. These compounds were also found to efficiently inhibit the molecular target for gold compounds, TrxR, and act as antifolate inhibitors. The research suggests that these gold compounds could be promising candidates for the development of updated therapies for NSCLC. [Extracted from the article]

A report from Universiti Kebangsaan Malaysia discusses the role of DNA methylation and DNA methyltransferases (DNMTs) as potential biomarkers and therapeutic targets in non-small cell lung cancer (NSCLC). The research highlights the increasing threat of lung cancer to the global healthcare system, particularly NSCLC, which is strongly associated with tobacco smoking. The study explores the epigenetic mechanisms involved in tumorigenesis and cancer progression, focusing on DNA methylation and its influence on gene regulation. Abnormalities in DNMTs can lead to disrupted gene regulation and cellular functions, and the review suggests that targeting DNMTs could be a potential therapeutic strategy for NSCLC. [Extracted from the article]

A study conducted in Shanxi, People's Republic of China, examined the efficacy and safety of combining Apatinib with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in the treatment of non-small cell lung cancer (NSCLC) patients with acquired EGFR-TKI resistance. The study analyzed the clinical records of 106 NSCLC patients, with 52 patients receiving Apatinib combined with EGFR-TKI and 54 patients receiving standard chemotherapy. The results showed that Apatinib combined with EGFR-TKI had similar efficacy to standard chemotherapy, but was associated with longer progression-free survival (PFS) and no significant increase in adverse reactions. [Extracted from the article]

A recent study conducted by researchers from Ningbo University explores the role of circLIFRSA in the PTEN/AKT signaling pathway and its impact on non-small cell lung cancer (NSCLC). The study found that circLIFRSA expression was significantly reduced in NSCLC cells and tissues, indicating its potential as an early diagnostic biomarker for NSCLC. Additionally, circLIFRSA was shown to inhibit cell growth and proliferation while promoting apoptosis in NSCLC cells. The findings suggest that circLIFRSA could serve as a biomarker for early diagnosis and a potential therapeutic target in NSCLC. [Extracted from the article]